Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Apellis Pharmaceuticals I...

    NASDAQ: APLS · Real-Time Price · USD
    18.32
    -0.51 (-2.71%)
    At close: Jun 16, 2025, 3:59 PM
    18.30
    -0.11%
    After-hours: Jun 16, 2025, 04:04 PM EDT

    Apellis Pharmaceuticals Statistics

    Share Statistics

    Apellis Pharmaceuticals has 125.68M shares outstanding. The number of shares has increased by 3.42% in one year.

    Shares Outstanding

    n/a
    		 125.68M

    Shares Change (YoY)

    n/a
    		 3.42%

    Shares Change (QoQ)

    n/a
    		 0.9%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 103.36M

    Failed to Deliver (FTD) Shares

    n/a
    		 53

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 25.03M, so 19.92% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 25.03M

    Short % of Shares Out

    n/a
    		 19.92%

    Short % of Float

    n/a
    		 26.28%

    Short Ratio (days to cover)

    n/a
    		 9.96

    Valuation Ratios

    The PE ratio is -19.98 and the forward PE ratio is -30.38. Apellis Pharmaceuticals's PEG ratio is 0.31.

    PE Ratio

    n/a
    		 -19.98

    Forward PE

    n/a
    		 -30.38

    PS Ratio

    n/a
    		 5.06

    Forward PS

    n/a
    		 1.4

    PB Ratio

    n/a
    		 17.3

    P/FCF Ratio

    n/a
    		 -44.79

    PEG Ratio

    n/a
    		 0.31
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Apellis Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 4.25, with a Debt / Equity ratio of 2.06.

    Current Ratio

    n/a
    		 4.25

    Quick Ratio

    n/a
    		 3.81

    Debt / Equity

    n/a
    		 2.06

    Debt / EBITDA

    n/a
    		 -3.04

    Debt / FCF

    n/a
    		 -5.32

    Interest Coverage

    n/a
    		 -4.08

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $1,108,321.99

    Profits Per Employee

    n/a
    		 $-280,678.01

    Employee Count

    n/a
    		 705

    Asset Turnover

    n/a
    		 0.88

    Inventory Turnover

    n/a
    		 1.45

    Taxes

    Income Tax

    n/a
    		 1.16M

    Effective Tax Rate

    n/a
    		 -0.59%

    Stock Price Statistics

    The stock price has increased by -54.57% in the last 52 weeks. The beta is 0.67, so Apellis Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.67

    52-Week Price Change

    n/a
    		 -54.57%

    50-Day Moving Average

    n/a
    		 18.37

    200-Day Moving Average

    n/a
    		 26.96

    Relative Strength Index (RSI)

    n/a
    		 47.43

    Average Volume (20 Days)

    n/a
    		 2,649,447

    Income Statement

    In the last 12 months, Apellis Pharmaceuticals had revenue of 781.37M and earned -197.88M in profits. Earnings per share was -1.6.

    Revenue

    n/a
    		 781.37M

    Gross Profit

    n/a
    		 663.64M

    Operating Income

    n/a
    		 -164.98M

    Net Income

    n/a
    		 -197.88M

    EBITDA

    n/a
    		 -154.53M

    EBIT

    n/a
    		 -156.32M

    Earnings Per Share (EPS)

    n/a
    		 -1.6
    Full Income Statement

    Balance Sheet

    The company has 411.29M in cash and 469.78M in debt, giving a net cash position of -58.49M.

    Cash & Cash Equivalents

    n/a
    		 411.29M

    Total Debt

    n/a
    		 469.78M

    Net Cash

    n/a
    		 -58.49M

    Retained Earnings

    n/a
    		 -3.04B

    Total Assets

    n/a
    		 807.28M

    Working Capital

    n/a
    		 549.34M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -87.87M and capital expenditures -403K, giving a free cash flow of -88.27M.

    Operating Cash Flow

    n/a
    		 -87.87M

    Capital Expenditures

    n/a
    		 -403K

    Free Cash Flow

    n/a
    		 -88.27M

    FCF Per Share

    n/a
    		 -0.71
    Full Cash Flow Statement

    Margins

    Gross margin is 84.93%, with operating and profit margins of -21.11% and -25.32%.

    Gross Margin

    n/a
    		 84.93%

    Operating Margin

    n/a
    		 -21.11%

    Pretax Margin

    n/a
    		 -25.18%

    Profit Margin

    n/a
    		 -25.32%

    EBITDA Margin

    n/a
    		 -19.78%

    EBIT Margin

    n/a
    		 -21.11%

    FCF Margin

    n/a
    		 -11.3%

    Dividends & Yields

    APLS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for APLS is $32, which is 74.7% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $32

    Price Target Difference

    n/a
    		 74.7%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 20
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.4

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist